CLINICAL TRIALS PROFILE FOR QUININE SULFATE
✉ Email this page to a colleague
All Clinical Trials for QUININE SULFATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000706 ↗ | Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and eliminated through the kidneys in HIV infected patients. Part II studies the effect of probenecid and quinine on the same aspects. Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment. |
| NCT00726414 ↗ | A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2005-12-01 | The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions. |
| NCT00726895 ↗ | A Dose Proportionality Study of Quinine Sulfate Capsules Under Fasting Conditions | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2004-05-01 | The purpose of this study is to evaluate and compare the dose proportionality of 324 mg Quinine Sulfate capsules following a single oral dose (1 x 324 mg capsules versus 2 x 324 mg capsules) in healthy adult volunteers when administered under fasting conditions. |
| NCT00727272 ↗ | A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2004-02-01 | The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate 324 mg capsules, manufactured by the Mutual Pharmaceutical Company, to Quinine Sulphate 300 mg tablets, manufactured by the Government Pharmaceutical Organization, Bangkok Metropolis, Thailand, after single oral dose administration under fasting conditions. An additional purpose of this study is to evaluate the effect of food on the Mutual Pharmaceutical Company product. |
| NCT00779259 ↗ | Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2007-08-01 | In a prior in vitro study using human hepatocytes quinine was shown to induce the activity of Cytochrome p450 CYP 1A2. The present study will evaluate the extent to which quinine sulfate-related induction of this enzyme effects the pharmacokinetics of theophylline, a sensitive probe drug for the activity of CYP 1A2. It will also evaluate the effect of single-dose theophylline on the pharmacokinetics of steady-state quinine sulfate. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for QUININE SULFATE
Condition Name
Clinical Trial Locations for QUININE SULFATE
Trials by Country
Clinical Trial Progress for QUININE SULFATE
Clinical Trial Phase
Clinical Trial Sponsors for QUININE SULFATE
Sponsor Name
